Edwards Lifesciences
1,281 hedge funds and large institutions have $46.7B invested in Edwards Lifesciences in 2024 Q1 according to their latest regulatory filings, with 160 funds opening new positions, 437 increasing their positions, 461 reducing their positions, and 106 closing their positions.
56% more funds holding in top 10
Funds holding in top 10: 9 → 14 (+5)
51% more first-time investments, than exits
New positions opened: 160 | Existing positions closed: 106
26% more capital invested
Capital invested by funds: $37B → $46.7B (+$9.77B)
3% more funds holding
Funds holding: 1,245 → 1,281 (+36)
1.74% more ownership
Funds ownership: 79.75% → 81.48% (+1.7%)
10% more call options, than puts
Call options by funds: $431M | Put options by funds: $393M
5% less repeat investments, than reductions
Existing positions increased: 437 | Existing positions reduced: 461
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$425M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
+$256M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$250M |
| 4 |
Holocene Advisors
New York
|
+$211M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$201M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$573M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$225M |
| 3 |
SFFS
Stonehage Fleming Financial Services
St. Helier,
Jersey
|
-$175M |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$130M |
| 5 |
Neuberger Berman Group
New York
|
-$129M |
EW Hedge Fund Activity: Q1 2024 in Review
1,281 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2024, worth a combined $46.7B — up 26% from $37B a quarter earlier.
Buyers outnumbered sellers: 160 funds opened new EW positions and 106 closed out — a net gain of 54 holders — while 437 added to existing stakes and 461 trimmed.
The largest buyer was Winslow Capital Management, opening a new position worth an estimated $425M. The largest seller was Capital International Investors, cutting an estimated $573M.
- 1,281 institutional investors held Edwards Lifesciences (EW) as of Q1 2024, up from 1,245 in Q4 2023.
- Funds reported $46.7B of Edwards Lifesciences stock for Q1 2024, up 26% quarter-over-quarter.
- 160 funds opened new Edwards Lifesciences positions in Q1 2024 and 106 closed out, a net change of +54 holders.
- The largest Edwards Lifesciences buyer in Q1 2024 was Winslow Capital Management, an estimated $425M added.
- The largest Edwards Lifesciences seller in Q1 2024 was Capital International Investors, an estimated $573M sold.
Based on aggregated 13F filings for Q1 2024.